Molecular recognition at purine and pyrimidine nucleotide (P2) receptors

Current Topics in Medicinal Chemistry

Volumn 4, Issue 8, 2004, Pages 805-819

  Jacobson, Kenneth A ^a   Costanzi, Stefano ^a   Ohno, Michihiro ^a   Joshi, Bhalchandra V ^a   Besada, Pedro ^a   Xu, Bin ^a   Tchilibon, Susanna ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; A 317491; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AR C126313; AR C69931X; CELL SURFACE RECEPTOR; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; ISOQUINOLINE DERIVATIVE; LIGAND; MRS 2279; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2X3 RECEPTOR; PURINE P2X7 RECEPTOR; PURINE P2Y RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PURINE P2Y2 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; PYRIDOXAL 5 PHOSPHATE DERIVATIVE; SURAMIN DERIVATIVE; THIOURACIL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING AFFINITY; CHANNEL GATING; CHEMICAL MODIFICATION; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; MOLECULAR LIBRARY; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENINE NUCLEOTIDES; ANIMALS; HUMANS; ION CHANNEL GATING; LIGANDS; MUTAGENESIS, SITE-DIRECTED; PURINE NUCLEOTIDES; RECEPTORS, PURINERGIC P2; URACIL NUCLEOTIDES;

EID: 3042765845     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043450961     Document Type: Review

References (78)

1. Burnstock, G. Introduction: P2 Receptors. This volume.
2. Abbracchio, M. P.; Burnstock, G. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 1998, 78, 113-145.
3. 14 receptor. Trends Pharmacol. Sci. 2003, 24, 52-55.
4. Müller, C. P2-Pyrimidinergic receptors and their ligands. Curr. Pharm. Des. 2002, 8, 2353-69.
5. Zimmermann, H.; Braun, N. Ecto-nucleotidases - molecular structures, catalytic properties, and functional roles in the nervous system. Prog. Brain Res. 1999, 120, 371-385.
6. Jacobson, K, A.; Jarvis, M. F.; Williams, M. Perspective: Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 2002, 45, 4057-4093.
7. Lambrecht, G. Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn Schmiedeberg's Arch. Pharmacol. 2000, 362, 340-50.
8. Von Kugelgen, I.; Wetter, A. Molecular pharmacology of P2Y-receptors. Naunyn Schmiedeberg's Arch. Pharmacol. 2000, 362, 310-23.
9. Khakh, B. S.; Burnstock, G., Kennedy, C.; King, B. F.; North, R. A.; Seguela, P.; Voigt, M.; Humphrey, P. P. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol. Rev. 2001, 53, 107-118.
10. Egan,T. M.; Cox, J. A.; Voigt, M. M. Molecular structure of P2X receptors. This volume.
11. King, B. F. Molecular biology of P2X purinoreceptors. In Cardiovascular Biology of Purines; Burnstock, G.; Dobson, Jr. J. G.; Liang, B. T.; Linden, J. Eds.; Kluwer Academic Publishers: Massachusetts, 1998, Ch. 10, pp 159-186.
12. North, R. A. P2X3 receptors and peripheral pain mechanisms. J. Physiol. 2003, In press.
13. Brown, S. G.; King B. F.; Kim Y. C.; Burnstock, G.; Jacobson, K. A. Drug Dev. Res. 2000, 49, 253-259.
14. Bianchi, B, R.; Lynch, K. J.; Touma, E.; Niforatos, W.; Burgard, E. C.; Alexander, K. M.; Park, H. S.; Yu, H.; Metzger, R.; Kowaluk, E.; Jarvis, M. F.; van Biesen, T. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur. J. Pharmacol. 1999, 376, 127-138.
15. Cinkilic, O.; King, B. F.; van der Giet, M.; Schluter, H.; Zidek, W.; Burnstock, G. Selective agonism of group I P2X receptors by dinucleotides dependent on a single adenine moiety. J. Pharmacol. Exp. Ther. 2001, 299, 131-136.
16. 1 receptors. Naunyn Schmiedeberg's Arch. Pharmacol. 2001, 34, 285-290.
17. Lambrecht, G.; Braun, K.; Damer, M.; Ganso, M.; Hildebrandt, C.; Ullmann, H.; Kassack, M. U.; Nickel, P. Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 2002, 8, 2371-2399.
18. Glänzel, M.; Bültmann, R.; Starke, K.; Frahm, A. W. Proceedings, XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, 2000.
19. 1 receptors. J. Med. Chem. 2001, 44, 340-349.
20. 3 receptors. Drug Devel. Res. 2001, 53, 281-291.
21. 2/3 heteromeric receptors. Br. J. Pharmacol. 2002, 135, 1524-1530.
22. 5I) is a potent antagonist at recombinant rat P2X'1 receptors. Br. J. Pharmacol. 1999, 128, 981-988.
23. Jarvis, M. F.; Burgard, E. C.; McGaraughty, S.; Honore, P.; Lynch, K.; Brennan, T. J.; Subieta, A.; Van Biesen, T.; Cartmell, J.; Bianchi, B.; Niforatos, W.; Kage, K.; Yu, H.; Mikusa, J.; Wismer, C. T.; Zhu, C. Z.; Chu, K.; Lee, C. H.; Stewart, A. O.; Polakowski, J.; Cox, B. F.; Kowaluk, E.; Williams, M.; Sullivan, J.; Faltynek, C. A-317491, A novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 17179-17184.
24. 7 nucleotide receptor: High selectivity for the human versus rat receptor homologues. Mol. Pharmacol. 1998, 54, 22-32.
25. 7 receptor antagonists: Probing multiple sites for linking and dimerization. Bioconj. Chem. 2002, 13, 1100-1111.
26. Alcaraz L.; Furber M.; Mortimore M. Adamantane derivatives. WO0061569, 2000.
27. Alcaraz, L.; Furber M,; Luker, T.; Mortimore, M.; Thorne, P. Adamantane derivatives. WO0142194, 2001.
28. Alcaraz, L.; Furber, M.; Adamantane derivatives. WO0194338, 2001.
29. Baxter, A.; Kindon, N.; Pairaudeau, G.; Roberts, B.; Thom, S. P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases. WO0144213, 2001.
30. Meghani, P.; Bennion, C. Novel piperidine and piperazine derivatives. WO0146200, 2001.
31. Boeynaems, Jean-Marie.; Wilkin, F.; Marteau, F.; Duhant, X.; Savi, P.; Gonzalez, N. S.; Robaye, B.; Communi, D. P2Y Receptors: New subtypes, new functions. Drug Devel. Res. 2003, 59, 30-35.
32. Diaz-Hernandez, M.; Pintor, J.; Miras-Portugal, M.T. Modulation of the dinucleotide receptor present in rat midbrain synaptosomes by adenosine and ATP. Br. J. Pharmacol. 2000, 130, 434-440.
33. Hollopeter, G.; Jantzen, H.-M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R. B.; Nurden, P.; Julius, D.; Conley, P. B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409, 202-207.
34. Marteau, F.; Le Poul, E.; Communi, D.; Labouret, C.; Savi, P.; Boeynaems, J. M.; Gonzalez, N.S. Pharmacological characterization of the human P2Y13 receptor. Mol. Pharmacol. 2003, 64, 104-112.
35. Lee, D. K.; Nguyen, T.; Lynch, K. R.; Cheng, R.; Vanti, W. B.; Arkhitko, O.; Lewis, T.; Evans, J. F.; George, S. R.; O'Dowd, B. F. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene, 2001, 275, 83-91.
36. 1 receptor: Molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J. Med. Chem., 1998, 41, 1456-1466.
37. Palmer, R. K.; Boyer, J. L.; Schacter, J. B.; Nicolas, R. A,; Harden, T. K. Discovery and mapping of ten novel G protein-coupled receptor genes. Mol. Pharmacol. 1998, 54, 1118-1123.
38. Fischer, B.; Boyer, J. L.; Hoyle, C. H. V.; Ziganshin, A. U.; Brizzolara, A. L.; Knight, G. E.; Zimmet, J.; Burnstock, G.; Harden, T. K.; Jacobson K. A. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5′-triphosphate. J. Med. Chem. 1993, 36, 3937-3946.
39. Boyer, J. L.; Siddiqi, S.; Fischer, B.; Romera-Avila, T.; Jacobson, K. A.; Harden, T. K. Identification of potent P2Y-purinoceptor agonists that are derivatives of adenosine 5′-monophosphate. Brit. J. Pharmacol. 1996, 118, 1959-1964.
40. Fischer, B.; Chulkin, A.; Boyer, J.L.; Harden, T.K,; Gendron, F.P.; Beaudoin, A.R.; Chapal, J.; Hillaire-Buys, D.; Petit, P. 2-Thioether 5′-O-(1-thiotriphosphate)adenosine derivatives as new insulin secretagogues acting through P2Y-receptors. J. Med. Chem. 1999, 42, 3636-3646.
41. Nahum, V.; Zundorf, G.: Levesque, S. A.; Beaudoin, A. R.; Reiser, G.; Fischer, B. Adenosine 5′-O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists. J. Med. Chem. 2002, 45, 5384-5396.
42. 1 receptor ligands. J. Med. Chem. 2000, 43, 829-842.
43. 6 receptors. J. Med. Chem. 2002, 45, 208-218.
44. 1 receptor agonists J. Med. Chem., 2002, 45, 2090-2100.
45. 1-receptor. Mol. Pharmacol. 1996, 50, 1323-1329.
46. 1 receptor antagonist. Br. J. Pharmacol. 2002, 135, 2004-2010.
47. 1 receptor with a high affinity radiolabeled antagonist. Mol. Pharmacol. 2002, 62, 1249-1257.
48. 1 receptor antagonist. Eur. J. Pharmacol. 2001, 412, 213-221.
49. Sak, K.; Uri, A.; Enkvist, E.; Raidaru, G.; Subbi, J.; Kelve, M.; Jarv, J. Adenosine-derived non-phosphate antagonists for P2Y(1) purinoceptors. Biochem. Biophys. Res. Commun. 2000, 272, 327-31.
50. Raboisson, P.; Baurand, A.; Cazenave, J. P.; Gachet, C.; Schultz, D; Spiess, B.; Bourguignon, J. J. A general approach toward the synthesis of C-nucleoside pyrazolo[1,5-a]-1,3,5-triazines and their 3′,5′-bisphosphate C-nucleotide analogues as the first reported in vivo stable P2Y(1)-receptor antagonists. J. Org. Chem. 2002, 67, 8063-8071.
51. 1 receptor: Structure activity relationships and receptor docking. J. Med. Chem. 2001, 44, 3092-3108.
52. Xu, B.; Stephens, A.; Kirschenheuter, G.; Greslin, A. F.; Cheng, X.; Sennelo, J.; Cattaneo, M.; Zighetti, M. L.; Chen, A.; Kim, S. A.; Kim, H. S.; Bischofberger, N.; Cook, G.; Jacobson, K. A. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: Phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J. Med. Chem. 2002, 45, 5694-5709.
53. 1 receptor-mediated responses. J. Auton. Nerv. Syst. 2000, 81, 171-77.
54. 1 receptor. Drug Devel. Res. 2002, 57, 173-181.
55. Coddou, C.; Loyola, G.; Boyer, J. L.; Bronfman, M.; Huidobro-Toro, J. P. The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists. FEBS Lett. 2003, 536, 145-150.
56. Glänzel, M.; Bültmann, R.; Starke, K.; Frahm A. W. Members of the acid blue 129 family as potent and selective P2Y-receptor antagonists. Drug Devel. Res. 2003, 59, 64-71.
57. 2T receptor: A novel approach to antithrombotic therapy. J. Med. Chem. 1999, 42, 213-220.
58. Bonnert, R. V.; Ingall, A. H.; Springthorpe, B.; Willis, P. A. Triazolo[4,5-D]pyrimidinyl derivatives and their use as medicaments. WO9828300, 1998.
59. Springthorpe, B. From ATP to AZD6140: Design of an orally active P2Y12 (P2T) receptor antagonist for the treatment of thrombosis. 225th ACS national meeting, Abstracts, Division of Medicinal Chemistry, 2003, 16.
60. Savi, P.; Pereillo, J. M.; Uzabiaga, M. F.; Combalbert, J.; Picard, C.; Maffrand, J. P.; Pascal, M.; Herbert, J. M. Identification and biological activity of the active metabolite of Clopidogrel. Thromb. Haemost. 2002, 84, 891-896.
61. i-linked P2T antagonist, CS-747. Br. J. Pharmacol. 2001, 132, 47-54.
62. 12). Bioorg. Med. Chem. Lett. 2001, 11, 1805-1808.
63. 12 platelet receptor. Haematologica 2002, 87S1, 22.
64. Taniguchi, M.; Nagai, K.; Arao, N.; Kawasaki, T.; Saito, T.; Moritani, Y.; Takasaki, J.; Hayashi, K.; Fujita, S.; Suzuki, K.-I.; Tsukamoto, S.-I. YM-254890, a novel platelet aggregation inhibitor produced by Chromobacterium sp. QS3666. J. Antibiot. 2003, 56, 358-363.
65. Harden, T. K. The G-protein-coupled P2Y receptors. In Cardiovascular Biology of Purines; Burnstock, G.; Dobson, Jr. J. G., Liang, B. T.; Linden, J. Eds.; Kluwer Academic Publishers: Massachusetts, 1998, Ch. 11, pp 187-205.
66. Malmsjö, M.; Adner, M.; Harden, T. K.; Pendergast, W.; Edvinsson, L.; Erlinge, D. The stable pyrimidines UDPβS and UTPγS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br. J. Pharmacol. 2000, 131, 51-56.
67. Pendergast, W.; Yerxa, B. R.; Douglass III, J. G.; Shaver, S. R.; Dougherty, R. W.; Redick C. C.; Sims, I. F.; Rideout J. Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5′-polyphosphates. Bioorg. Med. Chem. Lett. 2001, 11, 157-160.
68. Yerxa, B. R.; Sabater, J. R.; Davis, C. W.; Stutts, M. J.; Lang-Furr, M.; Picher, M.; Jones, A. C.; Cowlen, M.; Dougherty, R.; Boyer, J.; Abraham, W. M.; Boucher, R. C. Pharmacology of INS37217 [P(1)-(uridine 5′)-P(4)-(2′-deoxycytidine 5′ tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J. Pharmacol. Exp. Ther. 2002, 302, 871-880.
69. 4 receptor. Mol. Pharmacol. 2000, 57, 926-931.
70. Meghani, P. 11th RSC-SCI Medicinal Chemistry Symposium, Sept. 9-12, 2001 in Cambridge, UK.
71. Meghani, P. The design of P2Y2 antagonists for the treatment of inflammatory diseases. 224th ACS National meeting, Abstracts, Division of Medicinal Chemistry, 2002, 12.
72. Von Kügelgen, I.; Jacobson K. A. Blockade of P2Y6 receptors by diisothiocyanatostilbene-disulphonic acid (DIDS) and analogues. Abstr. German Pharmacol. Soc., Mainz, Germany (2001).
73. 2 receptor antagonists. Drug Devel. Res. 2003, 59, 72-81.
74. 2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J. Biol. Chem. 1995, 270, 4185-4188.
75. 1 receptor. Biochemistry, 1999, 38, 3498-3507.
76. Costanzi, S.; Jacobson, K. A. Structural comparison of P2Y receptors based on homology modeling. ACS National Meeting, New York, NY, Abstract MED1157, Sept. 9, 2003, In press.
77. 1 receptor in surface expression and activation processes. J. Biol. Chem. 1999, 274, 14639-14647.
78. 1 receptor. Mol. Pharmacol. 1997, 52, 499-507.